.jpg "Positive Report for Tandem Diabetes from Piper Jaffray")
In a report released today, Matthew O’Brien from Piper Jaffray upgraded Tandem Diabetes (NASDAQ: TNDM) to Buy. The company’s shares closed on Friday at $8.90.
According to TipRanks.com, O’Brien is a top 100 analyst with an average return of 25.2% and a 70.2% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Apollo Endosurgery Inc, and Merit Medical Systems.
Tandem Diabetes has an analyst consensus of Strong Buy, with a price target consensus of $6.
See today’s analyst top recommended stocks >>
Based on Tandem Diabetes’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $32.69 million. In comparison, last year the company had a GAAP net loss of $23.79 million.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNDM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tandem Diabetes Care, Inc. is a medical device company, which designs, develops and commercializes products for people with insulin dependent diabetes. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
Read More on TNDM:
